{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:23:27Z","timestamp":1782203007235,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.josat.2024.209391","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:26:17Z","timestamp":1715473577000},"page":"209391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes"],"prefix":"10.1016","volume":"164","author":[{"given":"Lindsey R.","family":"Hammerslag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Talbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetla","family":"Slavova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feitong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Fanucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209391_bb0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.18553\/jmcp.2019.19069","article-title":"Prior authorization and utilization management concepts in managed care pharmacy","volume":"25","author":"2018-2019 AMCP Pharmacy Professional Practice Committee","year":"2019","journal-title":"JMCP"},{"key":"10.1016\/j.josat.2024.209391_bb0010","doi-asserted-by":"crossref","unstructured":"21 CFR Part 1301 - Security Requirements, 2023. doi:https:\/\/doi.org\/10.3109\/9780203026656-11.","DOI":"10.3109\/9780203026656-11"},{"key":"10.1016\/j.josat.2024.209391_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","article-title":"A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices","volume":"54","author":"Andraka-Christou","year":"2018","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2024.209391_bb0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2105\/AJPH.2018.304856","article-title":"Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs","volume":"109","author":"Andrews","year":"2019","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.josat.2024.209391_bb0025","doi-asserted-by":"crossref","first-page":"w533","DOI":"10.1377\/hlthaff.28.4.w533","article-title":"What does it cost physician practices to interact with health insurance plans?: A new way of looking at administrative costs\u2014One key point of comparison in debating public and private health reform approaches","volume":"28","author":"Casalino","year":"2009","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2024.209391_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.therap.2020.05.007","article-title":"Prolonged-release buprenorphine formulations: Perspectives for clinical practice","volume":"75","author":"Chappuy","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.josat.2024.209391_bb0035","article-title":"Medicaid prescriptions for extended-release medications to treat opioid use disorder: State trends from 2011 to 2018","volume":"44","author":"Clemans-Cope","year":"2020","journal-title":"Urban Institute"},{"key":"10.1016\/j.josat.2024.209391_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: Update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209391_bb0045","series-title":"How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency","author":"DEA \/ Diversion Control Division","year":"2020"},{"key":"10.1016\/j.josat.2024.209391_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36914","article-title":"Telemedicine buprenorphine initiation and retention in OUD treatment in Medicaid enrollees","volume":"6","author":"Hammerslag","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209391_bb0055","series-title":"Drug Overdose Deaths in the United States, 1999\u20132020. NCHS Data Brief, No 428. Hyattsville, MD: National Center for Health Statistics","author":"Hedegaard","year":"2021"},{"key":"10.1016\/j.josat.2024.209391_bb0060","series-title":"Risk Evaluation and Mitigation Strategy (REMS) document SUBLOCADE (buprenorphine extended-release) REMS program (FDA application Num: NDA 209819, Issued 11\/2017)","author":"Indivior, Inc","year":"2021"},{"key":"10.1016\/j.josat.2024.209391_bb0065","series-title":"Prescribing Information | SUBLOCADE\u00ae (buprenorphine extended-release) injection, for subcutaneous use (CIII) 47","author":"Indivior, Inc","year":"2021"},{"issue":"166","key":"10.1016\/j.josat.2024.209391_bb0070","article-title":"2013 NCHS urban-rural classification scheme for counties. National Center for Health Statistics","volume":"2","author":"Ingram","year":"2014","journal-title":"Vital Health Statistics"},{"key":"10.1016\/j.josat.2024.209391_bb0075","series-title":"Medicaid COVID-19 FAQs","author":"Kentucky Cabinet for Health and Family Services Department for Medicaid Services","year":"2022"},{"key":"10.1016\/j.josat.2024.209391_bb0080","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(18)32428-0","article-title":"Opioid addiction: Long-acting formulations for a long-term disorder","volume":"393","author":"Kun\u00f8e","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.josat.2024.209391_bb0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.josat.2024.209391_bb0090","series-title":"Removing regulatory barriers to telehealth before and after COVID-19. Brookings 24","author":"Lee","year":"2020"},{"key":"10.1016\/j.josat.2024.209391_bb0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jrh.12669","article-title":"Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky","volume":"39","author":"Lei","year":"2023","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.josat.2024.209391_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209391_bb0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5694\/mja2.52250","article-title":"The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019\u20132022: Longitudinal sales data analysis","volume":"220","author":"Lintzeris","year":"2024","journal-title":"Medical Journal of Australia"},{"key":"10.1016\/j.josat.2024.209391_bb0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization: Buprenorphine trajectories and outcomes","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2024.209391_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106756","article-title":"Long-acting buprenorphine injectables: Opportunity to improve opioid use disorder treatment among rural populations","volume":"152","author":"Lofwall","year":"2021","journal-title":"Preventive Medicine"},{"key":"10.1016\/j.josat.2024.209391_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209391_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3132","article-title":"Association of formulary prior authorization policies with buprenorphine-naloxone prescriptions and hospital and emergency department use among medicare beneficiaries","volume":"3","author":"Mark","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209391_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108776","article-title":"Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health","volume":"139","author":"Martin","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209391_bb0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev-publhealth-040617-013526","article-title":"Treatment and prevention of opioid use disorder: Challenges and opportunities","volume":"39","author":"McCarty","year":"2018","journal-title":"Annual Review of Public Health"},{"key":"10.1016\/j.josat.2024.209391_bb0140","series-title":"Medi-Span Generic Product Identifier (GPI)","author":"Medi-Span","year":"2022"},{"key":"10.1016\/j.josat.2024.209391_bb0145","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.sapharm.2019.08.031","article-title":"Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review","volume":"16","author":"Mishuk","year":"2020","journal-title":"Research in Social and Administrative Pharmacy"},{"key":"10.1016\/j.josat.2024.209391_bb0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3122\/jabfm.2013.01.120062","article-title":"The impact of prior authorization requirements on primary care physicians\u2019 offices: Report of two parallel network studies","volume":"26","author":"Morley","year":"2013","journal-title":"The Journal of the American Board of Family Medicine"},{"key":"10.1016\/j.josat.2024.209391_bb0155","series-title":"3175 continuity of pharmacotherapy for opioid use disorder; behavioral health 2016\u20132017 technical report","author":"National Quality Forum","year":"2017"},{"key":"10.1016\/j.josat.2024.209391_bb0160","series-title":"DEA068 \u2013 March 31, 2020","author":"Prevoznik","year":"2020"},{"key":"10.1016\/j.josat.2024.209391_bb0165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid: The impact of longer treatment on health care outcomes for opioid use disorder within a key population of Medicaid enrollees","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2024.209391_bb0170","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209391_bb0175","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/ajhp\/zxac269","article-title":"Utility of an integrated health system specialty pharmacy in provision of extended-release buprenorphine for patients with opioid use disorder","volume":"80","author":"Shah","year":"2023","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.josat.2024.209391_bb0180","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: An overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.josat.2024.209391_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.16391","article-title":"Trends in drug overdose mortality rates in Kentucky, 2019-2020","volume":"4","author":"Slavova","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209391_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108661","article-title":"Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine","volume":"136","author":"Stein","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209391_bb0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018","volume":"326","author":"The Medicaid Outcomes Distributed Research Network (MODRN)","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2024.209391_bb0205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.18553\/jmcp.2018.24.4.329","article-title":"Increasing access to hepatitis C virus medications: A program model using patient navigators and specialty pharmacy to obtain prior authorization approval","volume":"24","author":"Vu","year":"2018","journal-title":"JMCP"},{"key":"10.1016\/j.josat.2024.209391_bb0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209391_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108335","article-title":"The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices","volume":"217","author":"Walsh","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209391_bb0220","first-page":"8","article-title":"A physician-friendly alternative to prior authorization for prescription drugs","volume":"15","author":"Wegner","year":"2009","journal-title":"The American Journal of Managed Care"},{"key":"10.1016\/j.josat.2024.209391_bb0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"AJP"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924001036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924001036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T09:18:46Z","timestamp":1728638326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924001036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":44,"alternative-id":["S2949875924001036"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209391","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209391"}}